Commission Regulation (EC) No 1102/95 of 16 May 1995 amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (Text with EEA relevance)
Date: 1995-05-16
Institutions: European Commission
Subjects: animal product, food inspection, health control, medicinal product, veterinary medicinal product, waste








L_1995110EN.01000901.xml










17.5.1995   


EN


Official Journal of the European Communities


L 110/9





COMMISSION REGULATION (EC) No 1102/95
of 16 May 1995
amending Annexes I, II and III of Council Regulation (EEC) No 2377/90 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin
(Text with EEA relevance)
THE COMMISSION OF THE EUROPEAN COMMUNITIES,
Having regard to the Treaty establishing the European Community,
Having regard to Council Regulation (EEC) No 2377/90 of 26 June 1990 laying down a Community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin (1), as last amended by Commission Regulation (EC) No 3059/94 (2), and in particular Articles 6, 7 and 8 thereof,
Whereas, in accordance with Regulation (EEC) No 2377/90, maximum residue limits must be established progressively for all pharmacologically active substances which are used within the Community in veterinary medicinal products intended for administration to food-producing animals;
Whereas maximum residue limits should be established only after the examination within the Committee for Veterinary Medicinal Products of all the relevant information concerning the safety of residues of the substance concerned for the consumer of foodstuffs of animal origin and the impact of residues on the industrial processing of foodstuffs;
Whereas, in establishing maximum residue limits for residues of veterinary medicinal products in foodstuffs of animal origin, it is necessary to specify the animal species in which residues may be present, the levels which may be present in each of the relevant meat tissues obtained from the treated animal (target tissue) and the nature of the residue which is relevant for the monitoring of residues (marker residue);
Whereas, for the control of residues, as provided for in appropriate Community legislation, maximum residue limits should usually be established for the target tissues of liver or kidney; whereas, however, the liver and kidney are frequently removed from carcasses moving in international trade, and maximum residue limits should therefore also always be established for muscle or fat tissues;
Whereas, in the case of veterinary medicinal products intended for use in laying birds, lactating animals or honey bees, maximum residue limits must also be established for eggs, milk or honey;
Whereas tilmicosin should be inserted into Annex I to Regulation (EEC) No 2377/90;
Whereas based on the current use in veterinary practice romifidine, detomidine, human chorion gonadotrophin, brotizolam, calcium hypophosphite, calcium acetate, calcium propionate, calcium benzoate, calcium malate, calcium chloride, calcium sulphate, calcium hydroxide, calcium oxide, calcium phosphate, calcium polyphos-phates, calcium silicate, calcium gluconate, calcium carbonate and calcium stearate should be inserted into Annex II to Regulation (EEC) No 2377/90;
Whereas human chorion gonadotrophin, calcium hypo-phosphite, calcium acetate, calcium propionate, calcium benzoate, calcium malate, calcium chloride, calcium sulphate, calcium hydroxide, calcium oxide, calcium phosphate, calcium polyphosphates, calcium silicate, calcium gluconate, calcium carbonate and calcium stearate should be inserted into Annex II to Regulation (EEC) No 2377/90: by extrapolation of scientific data this classification into Annex II shall apply to all food-producing animals;
Whereas, in order to allow for the completion of scientific studies, netobimin should be inserted into Annex III to Regulation (EEC) No 2377/90;
Whereas a period of 60 days should be allowed before the entry into force of this Regulation in order to allow Member States to make any adjustment which may be necessary to the authorizations to place the veterinary medicinal products concerned on the market which have been granted in accordance with Council Directive 81/851/EEC (3), as last amended by Directive 93/40/EEC (4), to take account of the provisions of this Regulation;
Whereas the measures provided for in this Regulation are in accordance with the opinion of the Committee for the Adaptation to Technical Progress of the Directives on the Removal of Technical Barriers to Trade in the Veterinary Medicinal Products Sector,
HAS ADOPTED THIS REGULATION:
Article 1
Annexes I, II and III of Regulation (EEC) No 2377/90 are hereby amended as set out in the Annex hereto.
Article 2
This Regulation shall enter into force on the sixtieth day following its publication in the Official Journal of the European Communities.

This Regulation shall be binding in its entirety and directly applicable in all Member States.
Done at Brussels, 16 May 1995.


For the Commission

Martin BANGEMANN

Member of the Commission





(1)  OJ No L 224, 18. 8. 1990, p. 1.

(2)  OJ No L 323, 16. 12. 1994, p. 15.

(3)  OJ No L 317, 6. 11. 1981, p. 1.

(4)  OJ No L 214, 24. 8. 1993, p. 31.


ANNEX






A.


Annex I is modified as follows:






1.


Anti-infectious agents






1.2.4.


Macrolides










Pharmacologically active substance(s)


Marker residue


Animal species


MRLs


Target tissues


Other provisions










1.2.4.2.


Tilmicosin






Tilmicosin


Ovine


1 000 μg/kg


Liver, kidney,


 




Porcine


50 μg/kg


Muscle, fat




Ovine


50 μg/l


Milk






















B.


In Annex II, point ‘1. Inorganic compounds’ the following heading added:






1.


Inorganic chemicals







Pharmacologically Active Substances(s)


Animal Species


Other provisions










1.5.


Calcium acetate
Calcium benzoate
Calcium carbonate
Calcium chloride
Calcium gluconate
Calcium hydroxide
Calcium hypophosphite
Calcium malate
Calcium oxide
Calcium phosphate
Calcium polyphosphates
Calcium propionate
Calcium silicate
Calcium stearate
Calcium sulphate






All food producing species


 








In Annex II, point ‘2. Organic compounds’ the following heading added:






2.


Organic compounds







Pharmacologically active substances(s)


Animal Species


Other provisions










2.12.


Romifidine






Equidae


For therapeutic uses only










2.13.


Detomidine






Bovine, equidae


For therapeutic uses only










2.14.


Brotizolam






Bovine


For therapeutic uses only










2.15.


Human chorion gonadotrophin (HCG)






All food producing species


 


















C.


Annex III is modified as follows:






2.


Antiparasitic agents






2.1.


Agents acting against endo-parasites






2.1.1.


Benzimidazoles and pro-benzimidazoles










Pharmacologically active substance(s)


Marker residue


Animal species


MRLs


Target tissues


Other provisions










2.1.1.7.


Netobimin






Sum of netobimin and albendazole and metabolites of albendazole measured as 2-amino-benzimidazole sulphone


Bovine, ovine, caprine


1 000 μg/kg


Liver


Provisional MRLs expire on 31 July 1997




500 μg/kg


Kidney




100 μg/kg


Muscle, fat




100 μg/kg


Milk